disease pathophysiology, i.e. link the molecular phenotype to clinical symptoms and have the potential to facilitate earlier, more accurate diagnosis and monitoring of disease progression. In AD, PET amyloid ligands enable in vivo mapping of cerebral Aβ deposition,2 whereas structural MRI has been shown to reflect HP-tau-related neurodegeneration.3 These biomarkers have recently been incorporated into the new AD diagnostic criteria.4,5 In disorders such as PD, FTD and DLB, structural biomarkers have clarified disease pathophysiology by showing patterns of atrophy associated with histopathology on the one hand,6-8 and clinical symptoms on the other (Table 1).8,9
